Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal cancer
Colorectal Cancer Metastatic
DRUG: Group A|DRUG: Group B
PFS, Progression free survival, through study completion, an average of 1 year
ORR, Objective response rate, up to 24 weeks|DOR, Duration of response, up to 24 weeks|DCR, Disease control rate, up to 24 weeks|OS, Overall survival, through study completion, an average of 2 year
The regimen involves 3-week cycles with bevacizumab (7.5 mg/m2 on days 1) and fixed doses of sintilimab (200 mg on day 1) and chemotherapy. The primary endpoint is progression-free survival (PFS). Secondary endpoints are Objective response rate(ORR), Disease control rate(DCR), Overall survival(OS) and quality of life. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0.